Plasma lactate dehydrogenase as a prognostic marker for nodal diffuse large B-cell lymphoma in dogs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16170%2F19%3A43878123" target="_blank" >RIV/62157124:16170/19:43878123 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Plasma lactate dehydrogenase as a prognostic marker for nodal diffuse large B-cell lymphoma in dogs

Popis výsledku v původním jazyce

Plasma lactate dehydrogenase (LDH) activity is a nonspecific prognostic marker of human diffuse large B-cell lymphoma (DLBCL) where high pretreatment activities (?2x the upper limit of normal, ULN) are associated with inferior survival, and treatment response. In contrast, existing veterinary studies were not able to confirm this phenomenon. However, studies where LDH activity was investigated in a single WHO-subtype are lacking. The aim of this retrospective study was to assess the predictive value of increased pretreatment LDH activity (?2x ULN) in terms of survival and treatment response in canine nodal DLBCL of various stages treated with CHOP between 2008-2019. Visibly hemolyzed samples were excluded to improve result reliability. Fifty-two included patients were included: 28/52 (54%) dogs had pretreatment LDH activity ?2x ULN. LDH activity was independent from age, weight, sex of patients, as well as grade, stage, and substage of lymphoma. High LDH activity was negatively linked to treatment response after induction chemotherapy (P=0.015) and positively linked to the presence of B symptoms (P=0.014). High LDH activity was associated with shorter progression free survival (120 vs. 396 days, P=0.001) and lymphoma-specific survival (186 vs. 469 days, P=0.001). In conclusion, high LDH activity (?2x ULN) was identified as a predictor of inferior treatment response and survival in the cohort of dogs with nodal DLBCL analyzed in this study. However, prospective studies assessing LDH in a larger cohort of patients and in different lymphoma WHO-subtypes are warranted.

Název v anglickém jazyce

Plasma lactate dehydrogenase as a prognostic marker for nodal diffuse large B-cell lymphoma in dogs

Popis výsledku anglicky

Plasma lactate dehydrogenase (LDH) activity is a nonspecific prognostic marker of human diffuse large B-cell lymphoma (DLBCL) where high pretreatment activities (?2x the upper limit of normal, ULN) are associated with inferior survival, and treatment response. In contrast, existing veterinary studies were not able to confirm this phenomenon. However, studies where LDH activity was investigated in a single WHO-subtype are lacking. The aim of this retrospective study was to assess the predictive value of increased pretreatment LDH activity (?2x ULN) in terms of survival and treatment response in canine nodal DLBCL of various stages treated with CHOP between 2008-2019. Visibly hemolyzed samples were excluded to improve result reliability. Fifty-two included patients were included: 28/52 (54%) dogs had pretreatment LDH activity ?2x ULN. LDH activity was independent from age, weight, sex of patients, as well as grade, stage, and substage of lymphoma. High LDH activity was negatively linked to treatment response after induction chemotherapy (P=0.015) and positively linked to the presence of B symptoms (P=0.014). High LDH activity was associated with shorter progression free survival (120 vs. 396 days, P=0.001) and lymphoma-specific survival (186 vs. 469 days, P=0.001). In conclusion, high LDH activity (?2x ULN) was identified as a predictor of inferior treatment response and survival in the cohort of dogs with nodal DLBCL analyzed in this study. However, prospective studies assessing LDH in a larger cohort of patients and in different lymphoma WHO-subtypes are warranted.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

40301 - Veterinary science

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů